Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography

[1]  E H Cook,et al.  Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. , 1998, The American journal of psychiatry.

[2]  C. Nemeroff,et al.  The serotonin transporter and depression , 1998, Depression and anxiety.

[3]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[4]  C. Nemeroff,et al.  Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hypercorticosteronemia, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat. , 1996, The Journal of pharmacology and experimental therapeutics.

[5]  P Riederer,et al.  Allelic Variation of Human Serotonin Transporter Gene Expression , 1996, Journal of neurochemistry.

[6]  G. Goodwin,et al.  Polymorphism in serotonin transporter gene associated with susceptibility to major depression , 1996, The Lancet.

[7]  Stanley J. Watson,et al.  Biology of schizophrenia and affective disease , 1996 .

[8]  K. Krishnan,et al.  Further studies on platelet serotonin transporter binding in depression. , 1994, The American journal of psychiatry.

[9]  Robert B. Innis,et al.  Graphical, Kinetic, and Equilibrium Analyses of in vivo [123I]β-CIT Binding to Dopamine Transporters in Healthy Human Subjects , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  C. Salmond,et al.  Is platelet imipramine binding reduced in depression? A meta-analysis , 1994, Biological Psychiatry.

[11]  P B Hoffer,et al.  Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  Jean Logan,et al.  Imaging endogenous dopamine competition with [11C]raclopride in the human brain , 1994, Synapse.

[13]  Marc Laruelle,et al.  Methyl 3β‐(4‐[125I]Iodophenyl)Tropane‐2β‐Carboxylate In Vitro Binding to Dopamine and Serotonin Transporters Under “Physiological” Conditions , 1994 .

[14]  D. Mash,et al.  Visualizing Dopamine and Serotonin Transporters in the Human Brain with the Potent Cocaine Analogue [125I]RTI‐55: In Vitro Binding and Autoradiographic Characterization , 1994, Journal of neurochemistry.

[15]  C. Nemeroff,et al.  Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. , 1994, Clinical chemistry.

[16]  F I Carroll,et al.  [125I]RTI‐55 Binding to Cocaine‐Sensitive Dopaminergic and Serotonergic Uptake Sites in the Human Brain , 1993, Journal of neurochemistry.

[17]  Robert B. Innis,et al.  Evaluation of the monoamine uptake site ligand [131I]methyl 3β-(4-Iodophenyl)-tropane-2β-carboxylate ([123I]β-CIT) in non-human primates: Pharmacokinetics, biodistribution and SPECT brain imaging coregistered with MRI , 1993 .

[18]  Marc Laruelle,et al.  SPECT imaging of dopamine and serotonin transporters with [123I]β‐CIT: Pharmacological characterization of brain uptake in nonhuman primates , 1993, Synapse.

[19]  R. Innis,et al.  Binding of the cocaine analog 2 beta-carbomethoxy-3 beta-(4-[125I]iodophenyl)tropane to serotonin and dopamine transporters: different ionic requirements for substrate and 2 beta-carbomethoxy-3 beta-(4-[125I]iodophenyl)tropane binding. , 1993, Molecular pharmacology.

[20]  H N Wagner,et al.  A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  F I Carroll,et al.  High‐affinity binding of [125I]RTI‐55 to dopamine and serotonin transporters in rat brain , 1992, Synapse.

[22]  M. Kuhar,et al.  [123/125I]RTI‐55, an in vivo label for the serotonin transporter , 1992, Synapse.

[23]  Marc Laruelle,et al.  Amphetamine‐stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates , 1992, Synapse.

[24]  C. Mathis,et al.  [125I]5-iodo-6-nitro-2-piperazinylquinoline: a potent and selective ligand for the serotonin uptake complex. , 1992, European journal of pharmacology.

[25]  Jean Logan,et al.  Effects of endogenous dopamine on measures of [18F]N‐methylspiroperidol binding in the basal ganglia: Comparison of simulations and experimental results from PET studies in baboons , 1991, Synapse.

[26]  D. Wong,et al.  Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brain , 1991, Synapse.

[27]  A. Coppen,et al.  5-Hydroxytryptamine in Psychiatry , 1991 .

[28]  P. Plenge,et al.  Why some depressed patients may have low platelet 3H‐imipramine binding , 1990, Acta psychiatrica Scandinavica.

[29]  J. Csernansky,et al.  Intercorrelations among monoamine metabolite concentrations in human lumbar CSF are not due to a shared acid transport system , 1990, Biological Psychiatry.

[30]  B L Holman,et al.  Brain perfusion SPECT using an annular single crystal camera: initial clinical experience. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  J. De Keyser,et al.  Age‐related changes in the human nigrostriatal dopaminergic system , 1990, Annals of neurology.

[32]  J. Marcusson,et al.  High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue , 1989, Brain Research.

[33]  J. Palacios,et al.  Autoradiography of antidepressant binding sites in the human brain: localization using [3h]imipramine and [3h]paroxetine , 1988, Neuroscience.

[34]  J. Leysen,et al.  Platelet 3H-paroxetine binding in depressed patients , 1988, Psychiatry Research.

[35]  C. Nemeroff,et al.  Marked reduction in the number of platelet-tritiated imipramine binding sites in geriatric depression. , 1988, Archives of general psychiatry.

[36]  J. Marcusson,et al.  [3H]GBR-12935 binding to dopamine uptake sites in the human brain , 1988, Brain Research.

[37]  Marc Laruelle,et al.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites , 1988, Biological Psychiatry.

[38]  Thomas P. Kobylski,et al.  Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised , 1988 .

[39]  C. Mazure,et al.  Reliability and validity of the symptoms of major depressive illness. , 1986, Archives of general psychiatry.

[40]  M Linnoila,et al.  Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. , 1986, Journal of psychiatric research.

[41]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[42]  M. Briley,et al.  Tritiated imipramine binding sites are decreased in platelets of untreated depressed patients. , 1980, Science.

[43]  Lee-Tzuu Chang,et al.  A Method for Attenuation Correction in Radionuclide Computed Tomography , 1978, IEEE Transactions on Nuclear Science.

[44]  M. Åsberg,et al.  Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine , 1977, Clinical pharmacology and therapeutics.

[45]  W. Hays.  Statistics for the social sciences , 1973 .

[46]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[47]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[48]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.